| David A Medina, MD | |
|
15 E Arrellaga St, Santa Barbara, CA 93101-2531 | |
| (805) 965-1095 | |
| (805) 965-8905 |
| Full Name | David A Medina |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 15 E Arrellaga St, Santa Barbara, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013920214 | NPI | - | NPPES |
| GR0027590 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | C23020 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| David A Medina, MD 15 E Arrellaga St, Santa Barbara, CA 93101-2531 Ph: (805) 965-1095 | David A Medina, MD 15 E Arrellaga St, Santa Barbara, CA 93101-2531 Ph: (805) 965-1095 |
News Archive
Just weeks after Sierra Leone discharged its last patient, a new study reflects on the lessons learnt from the recent outbreak of Ebola, comparing it with that of AIDS in Africa in the early 1980s.
Student athletes will soon have access to free injury evaluations by an orthopaedic physician on Saturdays at the Andrews Institute for Orthopaedics & Sports Medicine.
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
"Hope for Haiti Now" (HFHN) today announced the distribution of $35M as the first installment of funds raised through the January 22nd telethon: "Hope for Haiti Now: A Global Benefit for Earthquake Relief." Six of the telethon beneficiaries (Oxfam America, Partners In Health, the American Red Cross, UNICEF, United Nations World Food Programme, and Yele Haiti Foundation) submitted proposals last week.
A proof-of-concept study carried out at UCL Institute of Ophthalmology with funding from Fight for Sight has highlighted the potential of a targeted antisense oligonucleotide therapy to treat Fuchs endothelial corneal dystrophy patients with a mutation in the TCF4 gene.
› Verified 5 days ago
Dr. Jenna Eve Holmen, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 400 W Pueblo St, Santa Barbara, CA 93105 Phone: 805-682-7111 | |
Patricia L Erbe, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 15 E Arrellaga St, Santa Barbara, CA 93101 Phone: 805-965-1095 Fax: 805-965-8905 | |
Cristina Santos Candido-vitto, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 427 W Pueblo St, Suite C, Santa Barbara, CA 93105 Phone: 805-569-7850 Fax: 805-682-1618 | |
Barbara J Donnelly, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: Pueblo At Bath Streets, Santa Barbara, CA 93102 Phone: 805-569-7510 Fax: 949-366-2390 | |
Augusto Julian Castaneda, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 601 E Arrellaga St, Suite 205, Santa Barbara, CA 93103 Phone: 805-963-4959 Fax: 805-963-0332 | |
Charish L Barry, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 510 W Pueblo St, Santa Barbara, CA 93105 Phone: 805-845-1221 Fax: 805-845-1224 |